Drug Trial Radar · NCT07181382
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
480
Planned (sponsor's estimate)
Start
Feb 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- GB002, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Chiesi Farmaceutici S.p.A.
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period. The primary objective of the PCP is to evaluate the effect of seralutinib on improving exercise capacity in subjects with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease. The primary objective of the LTE is to evaluate the long-term safety and tolerability of seralutinib.
Conditions
- Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions
PlaceboDrug
Matching capsule containing placebo
SeralutinibDrug
Capsule containing seralutinib
Generic Dry Powder InhalerDevice
Generic dry powder inhaler for seralutinib or placebo delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in distance achieved on the six-minute walk test (6MWT), from baseline to PCP Week 24Time frame: Baseline to PCP Week 24
- Incidence of treatment-emergent adverse eventsTime frame: From first dose of LTE study treatment through LTE Week 148
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Valley Advanced Lung Diseases Institute
Fresno, California
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
Pulmonary Associates of Richmond, Inc.
Richmond, Virginia
Hillel Yaffe Medical Center
Hadera, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.